Equities Analysts Offer Predictions for CATX Q1 Earnings

Perspective Therapeutics, Inc. (NYSE:CATX) – Equities research analysts at Lifesci Capital issued their Q1 2025 earnings per share (EPS) estimates for shares of Perspective Therapeutics in a research note issued on Thursday, March 27th. Lifesci Capital analyst D. Kennedy anticipates that the company will post earnings per share of ($0.28) for the quarter. Lifesci Capital currently has a “Strong-Buy” rating on the stock. The consensus estimate for Perspective Therapeutics’ current full-year earnings is ($0.88) per share. Lifesci Capital also issued estimates for Perspective Therapeutics’ Q2 2025 earnings at ($0.29) EPS, Q3 2025 earnings at ($0.30) EPS, Q4 2025 earnings at ($0.31) EPS and FY2025 earnings at ($1.10) EPS.

CATX has been the subject of a number of other research reports. Royal Bank of Canada reduced their price objective on shares of Perspective Therapeutics from $16.00 to $15.00 and set an “outperform” rating for the company in a research report on Thursday, March 27th. Cantor Fitzgerald raised Perspective Therapeutics to a “strong-buy” rating in a report on Tuesday, March 4th. HC Wainwright reaffirmed a “buy” rating and set a $10.00 price target on shares of Perspective Therapeutics in a research note on Monday. Scotiabank assumed coverage on shares of Perspective Therapeutics in a report on Friday, March 7th. They issued a “sector outperform” rating and a $15.00 price target for the company. Finally, Brookline Capital Management raised shares of Perspective Therapeutics to a “strong-buy” rating in a report on Monday, March 10th. One research analyst has rated the stock with a hold rating, eight have given a buy rating and three have given a strong buy rating to the company’s stock. According to data from MarketBeat, Perspective Therapeutics currently has a consensus rating of “Buy” and an average target price of $14.44.

Perspective Therapeutics Trading Down 8.0 %

NYSE:CATX opened at $1.96 on Monday. Perspective Therapeutics has a 1-year low of $1.90 and a 1-year high of $19.05. The firm’s fifty day moving average price is $2.88 and its 200 day moving average price is $6.10.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in CATX. Y Intercept Hong Kong Ltd purchased a new stake in shares of Perspective Therapeutics during the fourth quarter worth about $33,000. Aigen Investment Management LP purchased a new stake in Perspective Therapeutics in the 4th quarter worth approximately $34,000. National Bank of Canada FI grew its stake in Perspective Therapeutics by 549,900.0% in the 4th quarter. National Bank of Canada FI now owns 11,000 shares of the company’s stock worth $35,000 after acquiring an additional 10,998 shares during the period. ProShare Advisors LLC raised its holdings in Perspective Therapeutics by 49.1% in the 4th quarter. ProShare Advisors LLC now owns 15,225 shares of the company’s stock valued at $49,000 after acquiring an additional 5,011 shares during the last quarter. Finally, Vontobel Holding Ltd. purchased a new position in shares of Perspective Therapeutics during the 4th quarter worth $51,000. 54.66% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In related news, Director Robert F. Williamson III purchased 38,145 shares of the company’s stock in a transaction on Monday, March 31st. The stock was bought at an average price of $2.14 per share, with a total value of $81,630.30. Following the completion of the transaction, the director now owns 108,982 shares of the company’s stock, valued at approximately $233,221.48. This represents a 53.85 % increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Juan Graham purchased 33,333 shares of the business’s stock in a transaction dated Friday, March 28th. The stock was bought at an average cost of $2.25 per share, with a total value of $74,999.25. Following the completion of the acquisition, the chief financial officer now owns 35,354 shares of the company’s stock, valued at approximately $79,546.50. The trade was a 1,649.33 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last quarter, insiders acquired 115,696 shares of company stock worth $256,344. Insiders own 3.52% of the company’s stock.

About Perspective Therapeutics

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.